LV11882B - AMINOTETRALINE DERIVATIVES FOR TREATMENT OF CIRCULAR AND HUMAN DISEASES - Google Patents

AMINOTETRALINE DERIVATIVES FOR TREATMENT OF CIRCULAR AND HUMAN DISEASES Download PDF

Info

Publication number: LV11882B
Authority: LV; Latvia
Prior art keywords: chf; heart failure; therapy; methylaminotetralin; pharmaceutical compositions
Prior art date: 1995-03-17

Application number

LVP-97-166A

Other languages

English (en)

Latvian (lv)

Other versions

LV11882A (lv

Inventor

Paolo Chiesi

Stefano Bongrani

Roberta Razzetti

Maurizio Civelli

Alberto Umile

Original Assignee

Chiesi Farmaceutici S.P.A.

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1995-03-17

Filing date

1997-09-15

Publication date

1998-03-20

1997-09-15 Application filed by Chiesi Farmaceutici S.P.A. filed Critical Chiesi Farmaceutici S.P.A.

1997-12-20 Publication of LV11882A publication Critical patent/LV11882A/xx

1998-03-20 Publication of LV11882B publication Critical patent/LV11882B/en

Links

238000002560 therapeutic procedure Methods 0.000 title abstract description 15
JRZGPXSSNPTNMA-UHFFFAOYSA-N 1,2,3,4-tetrahydronaphthalen-1-amine Chemical class C1=CC=C2C(N)CCCC2=C1 JRZGPXSSNPTNMA-UHFFFAOYSA-N 0.000 title description 6
208000024172 Cardiovascular disease Diseases 0.000 title 1
206010019280 Heart failures Diseases 0.000 claims abstract description 24
239000008194 pharmaceutical composition Substances 0.000 claims abstract description 13
208000019622 heart disease Diseases 0.000 claims abstract description 9
238000002360 preparation method Methods 0.000 claims abstract description 8
238000011282 treatment Methods 0.000 claims description 12
150000003839 salts Chemical class 0.000 claims description 6
239000004480 active ingredient Substances 0.000 claims description 3
239000003085 diluting agent Substances 0.000 claims 1
239000002207 metabolite Substances 0.000 claims 1
239000000203 mixture Substances 0.000 claims 1
206010007559 Cardiac failure congestive Diseases 0.000 abstract description 16
208000020446 Cardiac disease Diseases 0.000 abstract description 5
OMMYLOLVPCCZQZ-UHFFFAOYSA-N [6-(methylamino)-1-(2-methylpropanoyloxy)-5,6,7,8-tetrahydronaphthalen-2-yl] 2-methylpropanoate Chemical compound C1=CC(OC(=O)C(C)C)=C(OC(=O)C(C)C)C2=C1CC(NC)CC2 OMMYLOLVPCCZQZ-UHFFFAOYSA-N 0.000 abstract description 5
TWTMQRXNAZGSCE-UHFFFAOYSA-N hydron;[6-(methylamino)-1-(2-methylpropanoyloxy)-5,6,7,8-tetrahydronaphthalen-2-yl] 2-methylpropanoate;chloride Chemical compound Cl.C1=CC(OC(=O)C(C)C)=C(OC(=O)C(C)C)C2=C1CC(NC)CC2 TWTMQRXNAZGSCE-UHFFFAOYSA-N 0.000 description 32
VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 29
150000001875 compounds Chemical class 0.000 description 20
MIMDMPWWTWVHFK-UHFFFAOYSA-N 6-(methylamino)-5,6,7,8-tetrahydronaphthalene-1,2-diol;hydrochloride Chemical compound Cl.C1=CC(O)=C(O)C2=C1CC(NC)CC2 MIMDMPWWTWVHFK-UHFFFAOYSA-N 0.000 description 19
230000000694 effects Effects 0.000 description 18
102000005962 receptors Human genes 0.000 description 15
108020003175 receptors Proteins 0.000 description 15
229960003638 dopamine Drugs 0.000 description 14
239000003814 drug Substances 0.000 description 12
230000003291 dopaminomimetic effect Effects 0.000 description 10
230000002093 peripheral effect Effects 0.000 description 9
230000009467 reduction Effects 0.000 description 8
241000700159 Rattus Species 0.000 description 7
229940079593 drug Drugs 0.000 description 7
230000000004 hemodynamic effect Effects 0.000 description 7
238000001802 infusion Methods 0.000 description 7
UCTWMZQNUQWSLP-VIFPVBQESA-N (R)-adrenaline Chemical compound CNC[C@H](O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-VIFPVBQESA-N 0.000 description 6
239000005557 antagonist Substances 0.000 description 6
230000000747 cardiac effect Effects 0.000 description 6
239000002934 diuretic Substances 0.000 description 6
229940030606 diuretics Drugs 0.000 description 6
239000000902 placebo Substances 0.000 description 6
229940068196 placebo Drugs 0.000 description 6
SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 description 5
230000005764 inhibitory process Effects 0.000 description 5
238000001990 intravenous administration Methods 0.000 description 5
230000002182 neurohumoral effect Effects 0.000 description 5
230000004044 response Effects 0.000 description 5
BHDFPNRSDABMPW-UHFFFAOYSA-N 6-(methylamino)-5,6,7,8-tetrahydronaphthalene-1,2-diol Chemical compound C1=CC(O)=C(O)C2=C1CC(NC)CC2 BHDFPNRSDABMPW-UHFFFAOYSA-N 0.000 description 4
208000001953 Hypotension Diseases 0.000 description 4
206010037368 Pulmonary congestion Diseases 0.000 description 4
230000004872 arterial blood pressure Effects 0.000 description 4
230000001077 hypotensive effect Effects 0.000 description 4
230000000144 pharmacologic effect Effects 0.000 description 4
230000003518 presynaptic effect Effects 0.000 description 4
230000009885 systemic effect Effects 0.000 description 4
UCTWMZQNUQWSLP-UHFFFAOYSA-N Adrenaline Natural products CNCC(O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-UHFFFAOYSA-N 0.000 description 3
108060003345 Adrenergic Receptor Proteins 0.000 description 3
102000017910 Adrenergic receptor Human genes 0.000 description 3
229940102884 adrenalin Drugs 0.000 description 3
230000027455 binding Effects 0.000 description 3
230000017531 blood circulation Effects 0.000 description 3
150000003943 catecholamines Chemical class 0.000 description 3
210000003710 cerebral cortex Anatomy 0.000 description 3
208000027744 congestion Diseases 0.000 description 3
230000008602 contraction Effects 0.000 description 3
230000002526 effect on cardiovascular system Effects 0.000 description 3
208000021822 hypotensive Diseases 0.000 description 3
230000006872 improvement Effects 0.000 description 3
238000000034 method Methods 0.000 description 3
230000036513 peripheral conductance Effects 0.000 description 3
230000009870 specific binding Effects 0.000 description 3
230000000638 stimulation Effects 0.000 description 3
208000024891 symptom Diseases 0.000 description 3
230000000304 vasodilatating effect Effects 0.000 description 3
230000024883 vasodilation Effects 0.000 description 3
UUUHXMGGBIUAPW-UHFFFAOYSA-N 1-[1-[2-[[5-amino-2-[[1-[5-(diaminomethylideneamino)-2-[[1-[3-(1h-indol-3-yl)-2-[(5-oxopyrrolidine-2-carbonyl)amino]propanoyl]pyrrolidine-2-carbonyl]amino]pentanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-3-methylpentanoyl]pyrrolidine-2-carbon Chemical compound C1CCC(C(=O)N2C(CCC2)C(O)=O)N1C(=O)C(C(C)CC)NC(=O)C(CCC(N)=O)NC(=O)C1CCCN1C(=O)C(CCCN=C(N)N)NC(=O)C1CCCN1C(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C1CCC(=O)N1 UUUHXMGGBIUAPW-UHFFFAOYSA-N 0.000 description 2
239000005541 ACE inhibitor Substances 0.000 description 2
241000283690 Bos taurus Species 0.000 description 2
241000208011 Digitalis Species 0.000 description 2
241001465754 Metazoa Species 0.000 description 2
241000283973 Oryctolagus cuniculus Species 0.000 description 2
102000004270 Peptidyl-Dipeptidase A Human genes 0.000 description 2
108090000882 Peptidyl-Dipeptidase A Proteins 0.000 description 2
206010047139 Vasoconstriction Diseases 0.000 description 2
230000004913 activation Effects 0.000 description 2
210000004404 adrenal cortex Anatomy 0.000 description 2
230000001800 adrenalinergic effect Effects 0.000 description 2
230000036586 afterload Effects 0.000 description 2
239000000556 agonist Substances 0.000 description 2
229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 description 2
230000036772 blood pressure Effects 0.000 description 2
230000002596 correlated effect Effects 0.000 description 2
201000010099 disease Diseases 0.000 description 2
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
FGXWKSZFVQUSTL-UHFFFAOYSA-N domperidone Chemical compound C12=CC=CC=C2NC(=O)N1CCCN(CC1)CCC1N1C2=CC=C(Cl)C=C2NC1=O FGXWKSZFVQUSTL-UHFFFAOYSA-N 0.000 description 2
229960001253 domperidone Drugs 0.000 description 2
239000003136 dopamine receptor stimulating agent Substances 0.000 description 2
231100000673 dose–response relationship Toxicity 0.000 description 2
238000001647 drug administration Methods 0.000 description 2
238000011156 evaluation Methods 0.000 description 2
230000002349 favourable effect Effects 0.000 description 2
238000001727 in vivo Methods 0.000 description 2
230000001939 inductive effect Effects 0.000 description 2
230000007246 mechanism Effects 0.000 description 2
210000003205 muscle Anatomy 0.000 description 2
230000036581 peripheral resistance Effects 0.000 description 2
239000000546 pharmaceutical excipient Substances 0.000 description 2
230000003389 potentiating effect Effects 0.000 description 2
230000002685 pulmonary effect Effects 0.000 description 2
230000002889 sympathetic effect Effects 0.000 description 2
238000012360 testing method Methods 0.000 description 2
210000001177 vas deferen Anatomy 0.000 description 2
230000025033 vasoconstriction Effects 0.000 description 2
BGRJTUBHPOOWDU-NSHDSACASA-N (S)-(-)-sulpiride Chemical compound CCN1CCC[C@H]1CNC(=O)C1=CC(S(N)(=O)=O)=CC=C1OC BGRJTUBHPOOWDU-NSHDSACASA-N 0.000 description 1
WVTXFXCXXUAZLK-UHFFFAOYSA-N 6-(methylamino)-5,6,7,8-tetrahydronaphthalene-1,2-diol;hydrobromide Chemical compound [Br-].C1=CC(O)=C(O)C2=C1CC([NH2+]C)CC2 WVTXFXCXXUAZLK-UHFFFAOYSA-N 0.000 description 1
101710129690 Angiotensin-converting enzyme inhibitor Proteins 0.000 description 1
101710086378 Bradykinin-potentiating and C-type natriuretic peptides Proteins 0.000 description 1
241000282472 Canis lupus familiaris Species 0.000 description 1
208000031229 Cardiomyopathies Diseases 0.000 description 1
JRWZLRBJNMZMFE-UHFFFAOYSA-N Dobutamine Chemical compound C=1C=C(O)C(O)=CC=1CCNC(C)CCC1=CC=C(O)C=C1 JRWZLRBJNMZMFE-UHFFFAOYSA-N 0.000 description 1
229940098778 Dopamine receptor agonist Drugs 0.000 description 1
108090000371 Esterases Proteins 0.000 description 1
206010050394 Hyperkaliuria Diseases 0.000 description 1
206010020772 Hypertension Diseases 0.000 description 1
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
208000004880 Polyuria Diseases 0.000 description 1
208000032023 Signs and Symptoms Diseases 0.000 description 1
239000000654 additive Substances 0.000 description 1
239000000853 adhesive Substances 0.000 description 1
230000001070 adhesive effect Effects 0.000 description 1
-1 adrenalin Chemical class 0.000 description 1
239000000674 adrenergic antagonist Substances 0.000 description 1
230000004075 alteration Effects 0.000 description 1
230000002562 anti-bronchospastic effect Effects 0.000 description 1
238000009530 blood pressure measurement Methods 0.000 description 1
210000004204 blood vessel Anatomy 0.000 description 1
230000036760 body temperature Effects 0.000 description 1
230000002490 cerebral effect Effects 0.000 description 1
238000006243 chemical reaction Methods 0.000 description 1
230000001684 chronic effect Effects 0.000 description 1
208000029078 coronary artery disease Diseases 0.000 description 1
239000003218 coronary vasodilator agent Substances 0.000 description 1
230000003247 decreasing effect Effects 0.000 description 1
230000035619 diuresis Effects 0.000 description 1
229960001089 dobutamine Drugs 0.000 description 1
210000001198 duodenum Anatomy 0.000 description 1
230000032050 esterification Effects 0.000 description 1
238000005886 esterification reaction Methods 0.000 description 1
150000002148 esters Chemical class 0.000 description 1
210000001105 femoral artery Anatomy 0.000 description 1
230000001435 haemodynamic effect Effects 0.000 description 1
230000013632 homeostatic process Effects 0.000 description 1
230000036543 hypotension Effects 0.000 description 1
230000001976 improved effect Effects 0.000 description 1
239000004615 ingredient Substances 0.000 description 1
239000003112 inhibitor Substances 0.000 description 1
230000000297 inotrophic effect Effects 0.000 description 1
230000003993 interaction Effects 0.000 description 1
210000004731 jugular vein Anatomy 0.000 description 1
230000036230 kaliuresis Effects 0.000 description 1
210000005240 left ventricle Anatomy 0.000 description 1
229960004145 levosulpiride Drugs 0.000 description 1
239000007788 liquid Substances 0.000 description 1
230000005923 long-lasting effect Effects 0.000 description 1
239000003550 marker Substances 0.000 description 1
230000005226 mechanical processes and functions Effects 0.000 description 1
210000001640 nerve ending Anatomy 0.000 description 1
239000000712 neurohormone Substances 0.000 description 1
210000000056 organ Anatomy 0.000 description 1
230000001575 pathological effect Effects 0.000 description 1
230000007170 pathology Effects 0.000 description 1
230000001991 pathophysiological effect Effects 0.000 description 1
230000003285 pharmacodynamic effect Effects 0.000 description 1
238000011458 pharmacological treatment Methods 0.000 description 1
230000012495 positive regulation of renal sodium excretion Effects 0.000 description 1
230000036316 preload Effects 0.000 description 1
239000000651 prodrug Substances 0.000 description 1
229940002612 prodrug Drugs 0.000 description 1
238000011084 recovery Methods 0.000 description 1
230000004895 regional blood flow Effects 0.000 description 1
230000002040 relaxant effect Effects 0.000 description 1
230000029058 respiratory gaseous exchange Effects 0.000 description 1
230000002441 reversible effect Effects 0.000 description 1
210000002966 serum Anatomy 0.000 description 1
210000002460 smooth muscle Anatomy 0.000 description 1
229910052708 sodium Inorganic materials 0.000 description 1
239000011734 sodium Substances 0.000 description 1
239000007787 solid Substances 0.000 description 1
210000002563 splenic artery Anatomy 0.000 description 1
230000002269 spontaneous effect Effects 0.000 description 1
238000012453 sprague-dawley rat model Methods 0.000 description 1
230000006641 stabilisation Effects 0.000 description 1
238000011105 stabilization Methods 0.000 description 1
230000008700 sympathetic activation Effects 0.000 description 1
210000002820 sympathetic nervous system Anatomy 0.000 description 1
208000011580 syndromic disease Diseases 0.000 description 1
230000001225 therapeutic effect Effects 0.000 description 1
210000001519 tissue Anatomy 0.000 description 1
210000003437 trachea Anatomy 0.000 description 1
230000001960 triggered effect Effects 0.000 description 1
230000002792 vascular Effects 0.000 description 1
230000002861 ventricular Effects 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/222—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having aromatic groups, e.g. dipivefrine, ibopamine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/136—Amines having aromatic rings, e.g. ketamine, nortriptyline having the amino group directly attached to the aromatic ring, e.g. benzeneamine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/221—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having an amino group, e.g. acetylcholine, acetylcarnitine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/55—Protease inhibitors
- A61K38/556—Angiotensin converting enzyme inhibitors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Public Health (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Epidemiology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Cardiology (AREA)
Emergency Medicine (AREA)
Vascular Medicine (AREA)
Heart & Thoracic Surgery (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Gastroenterology & Hepatology (AREA)
Immunology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Hospice & Palliative Care (AREA)
Urology & Nephrology (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

LVP-97-166A 1995-03-17 1997-09-15 AMINOTETRALINE DERIVATIVES FOR TREATMENT OF CIRCULAR AND HUMAN DISEASES LV11882B (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
IT95MI000532A IT1275935B1 (it)	1995-03-17	1995-03-17	Derivato di aminotetralina per la terapia di malattie cardiovascolari
PCT/EP1996/001060 WO1996029065A2 (en)	1995-03-17	1996-03-13	Aminotetralin derivative for the therapy of cardiovascular diseases

Publications (2)

Publication Number	Publication Date
LV11882A LV11882A (lv)	1997-12-20
LV11882B true LV11882B (en)	1998-03-20

Family

ID=11370947

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
LVP-97-166A LV11882B (en)	1995-03-17	1997-09-15	AMINOTETRALINE DERIVATIVES FOR TREATMENT OF CIRCULAR AND HUMAN DISEASES

Country Status (31)

Country	Link
US (2)	US6013678A (de)
EP (2)	EP1216702A3 (de)
JP (1)	JPH11502211A (de)
KR (1)	KR100391143B1 (de)
CN (1)	CN1112920C (de)
AT (1)	ATE218856T1 (de)
AU (1)	AU702656B2 (de)
BR (1)	BR9607996A (de)
CA (1)	CA2215671A1 (de)
CZ (1)	CZ288488B6 (de)
DE (1)	DE69621786T2 (de)
DK (1)	DK0814791T3 (de)
EA (1)	EA000937B1 (de)
EE (1)	EE04040B1 (de)
ES (1)	ES2177769T3 (de)
HK (1)	HK1048060A1 (de)
HU (1)	HUP9801686A3 (de)
IL (1)	IL117518A (de)
IT (1)	IT1275935B1 (de)
LT (1)	LT4355B (de)
LV (1)	LV11882B (de)
MX (1)	MX9706971A (de)
NO (1)	NO317402B1 (de)
NZ (1)	NZ303993A (de)
PL (1)	PL183347B1 (de)
PT (1)	PT814791E (de)
SI (1)	SI9620036B (de)
SK (1)	SK282952B6 (de)
TR (1)	TR199700963T1 (de)
WO (1)	WO1996029065A2 (de)
ZA (1)	ZA962073B (de)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JP2695157B2 (ja) *	1986-12-29	1997-12-24	松下電器産業株式会社	可変パイプラインプロセッサ
WO2000076544A1 (en) *	1996-03-13	2000-12-21	Chiesi Farmaceutici S.P.A.	Aminotetralin derivative for the therapy of cardiovascular diseases
SI1183046T1 (en) *	1999-06-09	2004-02-29	Chiesi Farmaceutici S.P.A.	Aminotetralin derivative for the therapy of cardiovascular diseases
CN1354676A (zh) *	1999-06-09	2002-06-19	奇斯药制品公司	用于心血管疾病疗法的氨基四氢化萘衍生物
IT1313583B1 (it) *	1999-07-30	2002-09-09	Chiesi Farma Spa	Derivati 2-amminotetralinici per la terapia del glaucoma.
IL152751A0 (en) *	2000-05-12	2003-06-24	Chiesi Farma Spa	Optically active 2-aminotetralin derivatives, the processes for the preparation thereof and the therapeutical use of pharmaceutical compositions containing them
SE0101854L (sv) *	2001-05-28	2002-11-29	Bioneris Ab	Användning av en förening med en negativt laddad region av grupper för behandling av restenos.
EP1384708A1 (de) *	2002-07-26	2004-01-28	CHIESI FARMACEUTICI S.p.A.	Verfahren zur Herstellung der Form I von Nolomirol Hydrochlorid
US20050101668A1 (en) *	2003-07-24	2005-05-12	Chiesi Farmaceutici S.P.A.	Aminotetralin derivatives as a medicament for the treatment and prevention of myocardial ischemic conditions

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4134997A (en) *	1977-03-01	1979-01-16	University Of Iowa Research Foundation	Effect of an aminotetralin derivative on coronary blood flow in infarcted hearts
SU998342A1 (ru)	1981-12-11	1983-02-23	Предприятие П/Я А-3732	Способ получени синтетического цеолита типа @
IT1218322B (it) *	1982-06-10	1990-04-12	Chiesi Farma Spa	Derivati di 1,2,3,4-tetraidronaftalene,procedimento di preparazione e relative composizioni farmaceutiche

1995
- 1995-03-17 IT IT95MI000532A patent/IT1275935B1/it active IP Right Grant
1996
- 1996-03-13 PT PT96907446T patent/PT814791E/pt unknown
- 1996-03-13 ES ES96907446T patent/ES2177769T3/es not_active Expired - Lifetime
- 1996-03-13 DK DK96907446T patent/DK0814791T3/da active
- 1996-03-13 CA CA002215671A patent/CA2215671A1/en not_active Abandoned
- 1996-03-13 BR BR9607996A patent/BR9607996A/pt not_active Application Discontinuation
- 1996-03-13 PL PL96322284A patent/PL183347B1/pl not_active IP Right Cessation
- 1996-03-13 AT AT96907446T patent/ATE218856T1/de not_active IP Right Cessation
- 1996-03-13 EP EP02001772A patent/EP1216702A3/de not_active Withdrawn
- 1996-03-13 KR KR1019970706438A patent/KR100391143B1/ko not_active Expired - Fee Related
- 1996-03-13 MX MX9706971A patent/MX9706971A/es not_active IP Right Cessation
- 1996-03-13 CN CN96193312A patent/CN1112920C/zh not_active Expired - Fee Related
- 1996-03-13 EE EE9700231A patent/EE04040B1/xx not_active IP Right Cessation
- 1996-03-13 DE DE69621786T patent/DE69621786T2/de not_active Expired - Fee Related
- 1996-03-13 EA EA199700243A patent/EA000937B1/ru not_active IP Right Cessation
- 1996-03-13 NZ NZ303993A patent/NZ303993A/xx unknown
- 1996-03-13 TR TR97/00963T patent/TR199700963T1/xx unknown
- 1996-03-13 SI SI9620036A patent/SI9620036B/sl not_active IP Right Cessation
- 1996-03-13 WO PCT/EP1996/001060 patent/WO1996029065A2/en not_active Ceased
- 1996-03-13 CZ CZ19972866A patent/CZ288488B6/cs not_active IP Right Cessation
- 1996-03-13 EP EP96907446A patent/EP0814791B1/de not_active Expired - Lifetime
- 1996-03-13 JP JP8528045A patent/JPH11502211A/ja not_active Ceased
- 1996-03-13 US US08/913,363 patent/US6013678A/en not_active Expired - Fee Related
- 1996-03-13 AU AU51072/96A patent/AU702656B2/en not_active Ceased
- 1996-03-13 SK SK1254-97A patent/SK282952B6/sk unknown
- 1996-03-13 HU HU9801686A patent/HUP9801686A3/hu unknown
- 1996-03-14 ZA ZA962073A patent/ZA962073B/xx unknown
- 1996-03-17 IL IL11751896A patent/IL117518A/en not_active IP Right Cessation
1997
- 1997-09-15 LV LVP-97-166A patent/LV11882B/en unknown
- 1997-09-15 LT LT97-147A patent/LT4355B/lt not_active IP Right Cessation
- 1997-09-16 NO NO19974267A patent/NO317402B1/no not_active IP Right Cessation
1999
- 1999-06-09 US US09/328,434 patent/US6103760A/en not_active Expired - Fee Related
2002
- 2002-12-19 HK HK02109206.9A patent/HK1048060A1/en unknown

Also Published As

Publication number	Publication date
SI9620036A (sl)	1998-02-28
AU5107296A (en)	1996-10-08
CN1112920C (zh)	2003-07-02
PL322284A1 (en)	1998-01-19
DE69621786T2 (de)	2003-01-02
LT4355B (lt)	1998-06-25
EP0814791B1 (de)	2002-06-12
AU702656B2 (en)	1999-02-25
NO317402B1 (no)	2004-10-25
CN1181699A (zh)	1998-05-13
PL183347B1 (pl)	2002-06-28
EP1216702A3 (de)	2002-09-04
EA199700243A1 (ru)	1998-02-26
NO974267L (no)	1997-11-07
SK282952B6 (sk)	2003-01-09
IL117518A0 (en)	1996-07-23
WO1996029065A3 (en)	1996-11-28
EP1216702A2 (de)	2002-06-26
DE69621786D1 (de)	2002-07-18
CZ288488B6 (en)	2001-06-13
KR19980703030A (ko)	1998-09-05
TR199700963T1 (xx)	1998-02-21
HUP9801686A2 (hu)	1999-06-28
EA000937B1 (ru)	2000-06-26
US6103760A (en)	2000-08-15
CA2215671A1 (en)	1996-09-26
DK0814791T3 (da)	2002-10-07
LT97147A (en)	1998-02-25
HK1048060A1 (en)	2003-03-21
IT1275935B1 (it)	1997-10-24
US6013678A (en)	2000-01-11
ES2177769T3 (es)	2002-12-16
WO1996029065A2 (en)	1996-09-26
EE04040B1 (et)	2003-06-16
NO974267D0 (no)	1997-09-16
KR100391143B1 (ko)	2003-11-28
LV11882A (lv)	1997-12-20
ZA962073B (en)	1996-11-27
EE9700231A (et)	1998-04-15
ITMI950532A0 (it)	1995-03-17
JPH11502211A (ja)	1999-02-23
SK125497A3 (en)	1998-02-04
NZ303993A (en)	2000-12-22
BR9607996A (pt)	1998-06-23
IL117518A (en)	2001-05-20
CZ286697A3 (cs)	1998-03-18
HK1004802A1 (en)	1998-12-11
ITMI950532A1 (it)	1996-09-17
HUP9801686A3 (en)	1999-10-28
EP0814791A1 (de)	1998-01-07
PT814791E (pt)	2002-10-31
MX9706971A (es)	1997-11-29
ATE218856T1 (de)	2002-06-15
SI9620036B (sl)	2002-10-31

Publication	Publication Date	Title
Kurien et al.	1971	The role of free fatty acids in the production of ventricular arrhythmias after acute coronary artery occlusion
Wilson et al.	1975	Effects of an orally administered prostaglandin analogue (16, 16-dimethyl prostaglandin E2) on human gastric secretion
EP0814791B1 (de)	2002-06-12	Aminotetralinderivat zur behandlung von herzkreislauferkrankung
EP1183046B1 (de)	2003-09-03	Aminotetralin derivate zur therapie der kardiovaskulären erkrankungen
WO2000076544A1 (en)	2000-12-21	Aminotetralin derivative for the therapy of cardiovascular diseases
HK1004802B (en)	2002-10-11	Aminotetralin derivative for the therapy of cardiovascular diseases
EP1331004A2 (de)	2003-07-30	Aminotetralin Derivat zur Behandlung von kardiovaskulären Erkrankungen
Prichard et al.	1981	Clinical features of adrenergic agonists and antagonists
Hieble et al.	1991	Therapeutic Applications of Agents Interacting with the ẞ-Adrenoceptor
Cohn et al.	2013	Mononitrates: International Symposium on Mononitrates Montreux, Suisse, June 14-16, 1984